New drug etrinabdione tested for leg artery disease
Disease control
Not yet recruiting
This Phase IIa trial tests the safety and tolerability of a new drug called etrinabdione in 30 adults with peripheral arterial disease (PAD). Participants take the drug twice daily for 12 months, starting with a low dose and possibly moving to a higher dose if safe. Researchers w…
Phase: PHASE2 • Sponsor: VivaCell Biotechnology España • Aim: Disease control
Last updated Jun 26, 2026 18:09 UTC